Business Context and Reporting Period
Cormedix Inc. (CRMD), a Delaware corporation, filed this Form 8-K on March 29, 2022. The filing serves to announce the Company's financial results for the fourth quarter and full year ended December 31, 2021. The report was signed by Matthew T. David, Interim Chief Executive Officer and Chief Financial Officer.
Key Financial Metrics
This Form 8-K is a current report referencing a press release (Exhibit 99.1) for detailed financial data. The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes
The filing text does not contain specific data regarding material changes in financial performance compared to prior periods. It solely references the issuance of the press release containing the Q4 and full-year 2021 results.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, or risk factors. It notes that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 29, 2022) for specific Q4 and full-year 2021 financial figures.
- Verify the Company's liquidity position and cash burn rate as detailed in the referenced press release.
- Confirm the status of the interim leadership team, specifically Matthew T. David's role as Interim CEO and CFO.
- Check for any subsequent filings that may incorporate the press release data by reference.